IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of STROBEL et al.

Examiner:

Kamal A Saeed

Art Unit:

1626

Application No.: 10/073,160

Filed:

February 13, 2002

Title: Acylated Indanyl Amines and Their Use as

Pharmaceuticals

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under §1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

\boxtimes	(b)	This Information Disclosure Statement is filed after the period set forth in 37 C.F.R.				
		1.97(b), but is believed to be filed before the mailing date of a final action under §1.113				
		or a	notice of allowance under §1.311, whichever occurs first.			
	***************************************	(1)	The undersigned attorney certifies that each item of information contained in this			
			Information Disclosure Statement was cited in a communication from a foreign			
			patent office in a counterpart foreign application not more than three months prior			
			to the filing of this statement;			
		(2)	The undersigned attorney certifies that no item of information contained in this			
			Information Disclosure Statement was cited in a communication from a foreign			
			patent office in a counterpart foreign application or, to the knowledge of the			
			undersigned attorney after making reasonable inquiry, was known to any			
			individual designated in §1.56(c) more than three months prior to the filing of this			
			statement; or			
	\boxtimes	(3)	This Information Disclosure Statement is accompanied by a transmittal letter in			
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is			
			authorized.			
			Respectfully submitted,			
			/Joseph D. Rossi/			
			Joseph Rossi, Reg. No. 47,038			
	***		Attorney for Applicant			

Aventis Pharmaceuticals Inc. (a member of the sanofi-aventis group) U.S. Patent Operations Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-**3410** Telefax (908) 231-2626 Aventis Docket No. DEAV2001/0004 US NP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

Kamal A Saeed

STROBEL et al.

Art Unit:

1626

Application No.: 10/073,160

Filed:

February 13, 2002

Title: Acylated Indanyl Amines and Their Use as

Pharmaceuticals

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT FOR WHICH THE FEE SPECIFIED UNDER 37 C.F.R. 1.97(c) IS REQUIRED

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Enclosed is an Information Disclosure Statement for which the fee specified in 37 C.F.R. 1.97(c) is required.

Please charge Deposit Account No. 18-1982 in the amount of \$180.00. The Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

Respectfully submitted,

/Joseph D. Rossi/

Joseph D. Rossi, Reg. No. 47,038

Attorney for Applicant

sanofi-aventis U.S. LLC U.S. Patent Operations Route #202-206 / P.O. Box 6800 Bridgewater, New Jersey 08807-0800 Telephone (908) 231-3410 (908) 231-2626 Telefax

sanofi-aventis Docket No. DEAV2001/0004 US NP

Please type a plus sign (+) inside this box	→		
---	----------	--	--

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office: 0.5. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known				
Application Number	10/073,160			
Filing Date	02-13-2002			
First Named Inventor	STROBEL			
Group Art Unit	1626			
Examiner Name	SAEED, Kamal A.			
Attorney Docket Number	DEAV2001/0004 - US - NP			

	U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.1	U.S. Paten Number	t Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
				* * **********************************			
				WATER TO THE RESERVE			
		-					
	·						

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.1	Office	Foreign Patent Document Kind Code ⁸ Office ³ Number ⁴ (<i>if known</i>)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	1e	
		wo	91/17162		COOPER, et al.	11-14-1991			
		wo	02/20530		BARTLETT, et al.	03-14-2002			
								<u> </u>	
								<u> </u>	
								4	
		ļ						 	
		<u> </u>						 	
]			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.